nicht kleckern ..klotzen ::POZEN

8,945,621 on February 3, 2015. Horizon Pharma plc (NASDAQ: HZNP), which holds the U.S. NDA for VIMOVO, and POZEN plan to list the U.S. patent in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the eleventh U.S. patent to be listed in the Orange Book for VIMOVO. http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283

buran
 

..yöah  

Fourth Quarter and Year End 2014 Results
13:30 04.03.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release fourth quarter and year end 2014 results on March 9, 2015, before the market opens. http://www.ariva.de/news/...Quarter-and-Year-End-2014-Results-5301074  

webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The fourth quarter and year end 2014 earnings release will be accessible in the Media section of POZEN’s website. http://www.ariva.de/news/...Quarter-and-Year-End-2014-Results-5301074
 

..muha

buran & MARIO https://www.facebook.com/mario.meierhof/  

Results
12:30 09.03.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2014. http://www.ariva.de/news/...Quarter-and-Year-End-2014-Results-5304833  

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results, our ability to return value to our stockholders, including any cash distributions, and our future prospects could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to further license our YOSPRALA product candidates on terms and timing acceptable to us, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies or due to issues with third-party manufacturers, or the failure to obtain such approval of our product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO®, our dependence on Patheon for the manufacture of YOSPRALA 81/40 and YOSPRALA 325/40; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended September 30, 2014. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements. http://www.ariva.de/news/...Quarter-and-Year-End-2014-Results-5304833
 

First Quarter 2015 Results
22:05 04.05.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2015 results on May 8, 2015, before the market opens.

The announcement will be followed by a live webcast at 10:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The first quarter 2015 earnings release will be accessible in the Media section of POZEN’s website. http://www.ariva.de/news/...ast-of-First-Quarter-2015-Results-5356175  

13:40 08.05.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2015. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986  

Q1 2015 was the fourth consecutive quarter of positive cash flow.
Royalty revenue for Q1 2015 was $4.4 million compared to $4.5 million for Q1 2014.
Q1 2015 expenses decreased by $0.4 million to $4.2 million compared to Q1 2014.
In Q1 2015, POZEN announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled “Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer” that relates to VIMOVO® (naproxen/esomeprazole magnesium) delayed release tablets in patients taking low dose aspirin. The patent expires in October 2031.
http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986  

The Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 25, 2014 and on December 16, 2014 stating that satisfactory resolution of inspection deficiencies found during an inspection of the active ingredient supplier’s manufacturing facility in April 2014 was required before the Company’s New Drug Application (NDA) for YOSPRALA 81/40 or YOSPRALA 325/40 could be approved. There were no clinical or safety deficiencies noted with respect to either YOSPRALA 81/40 or YOSPRALA 325/40 and no other deficiencies were noted in either CRL. Final agreement on the draft product labeling is also pending. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986
 

For the first quarter of 2015, POZEN reported total revenue of $4.4 million, resulting from VIMOVO royalty. For the first quarter of 2014, the Company reported total revenue of $7.5 million, resulting from $4.5 million of VIMOVO royalty and $3.0 million of amortization of the upfront fee for licensing of YOSPRALA. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986
 

At March 31, 2015, cash and cash equivalents totaled $43.9 million, up $3.3 million from December 31, 2014. Accounts receivable totaled $4.4 million. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986
 

POZEN will host a webcast to present first quarter 2015 results and management’s outlook on Friday, May 8, 2015 at 10:00 a.m. (EDT). The webcast can be accessed live and will be available for replay at www.pozen.com. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986
 

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results, our ability to return value to our stockholders, including any cash distributions, and our future prospects could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to further license our YOSPRALA product candidates on terms and timing acceptable to us, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies or due to issues with third-party manufacturers, or the failure to obtain such approval of our product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO®, our dependence on Patheon for the manufacture of YOSPRALA 81/40 and YOSPRALA 325/40; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Annual Report on Form 10-K for the period ended December 31, 2014. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986
 

POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986
 

symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986

buran & MARIO https://www.facebook.com/mario.meierhof/  

POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
13:05 01.06.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman, Chief Executive Officer and President is retiring, effective immediately. Dr. Plachetka has also resigned from the Board of Directors of POZEN and has withdrawn as a nominee for election as a director at the 2015 Annual Meeting of Stockholders. http://www.ariva.de/news/...achetka-Adrian-Adams-Named-as-CEO-5382300  

an Intangible Property Transfer Arrangement
13:35 02.06.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to developing medicine that transforms lives, today announced that it has formed POZEN Limited, a wholly owned Irish subsidiary and has entered in an Intangible Property Transfer Arrangement between POZEN Inc. and POZEN Limited. http://www.ariva.de/news/...ble-Property-Transfer-Arrangement-5383649  

POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
16:50 08.06.15

CHAPEL HILL, N.C. & MILTON, Ontario --(BUSINESS WIRE)--

POZEN Inc. (“POZEN”) (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced the acquisition of Tribute Pharmaceuticals Canada Inc. (“Tribute”) (TSXV:TRX or OTCQX:TBUFF), a Canadian specialty pharmaceutical company, in a transaction valued at approximately US$146 million. Upon completion of the acquisition, which is expected to occur in the fourth quarter of 2015, the combined company will be named Aralez Pharmaceuticals plc (“Aralez” or the “Company”) and domiciled in Ireland. Upon closing, Aralez is expected to trade on NASDAQ and TSX. http://www.ariva.de/news/...-from-Leading-Healthcare-Sponsors-5388586  

13:35 22.06.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (“POZEN”) (NASDAQ:POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced appointments to its Executive Leadership Team led by newly appointed Chief Executive Officer, Adrian Adams. http://www.ariva.de/news/...nnounces-Key-Leadership-Additions-5400716  

of Finance
13:05 27.07.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (“POZEN”) (NASDAQ:POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that Scott Charles will be appointed Senior Vice President of Finance of POZEN, effective July 27th, with the intention of becoming Chief Financial Officer of Aralez Pharmaceuticals plc. upon completion of the pending merger of POZEN with Tribute Pharmaceuticals Canada Inc. Mr. Charles will report to Adrian Adams, Chief Executive Officer of POZEN, and will be responsible for all financial activities related to the integration of Tribute Pharmaceuticals upon its anticipated merger with POZEN and with respect to the implementation of all systems necessary for the planned transformation of POZEN and ultimately Aralez Pharmaceuticals into a commercial specialty pharmaceuticals company. He will also play a critical role on the leadership team. http://www.ariva.de/news/...-Senior-Vice-President-of-Finance-5435596  

POZEN Announces August 10th Webcast of Second Quarter 2015 Results
13:35 27.07.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN) announced today that it plans to release second quarter 2015 results on August 10, 2015, before the market opens.

The announcement will be followed by a live webcast at 2:00 p.m. (EDT) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The second quarter 2015 earnings release will be accessible in the Media section of POZEN’s website. http://www.ariva.de/news/...st-of-Second-Quarter-2015-Results-5435638  

POZEN Reports Second Quarter 2015 Results
13:05 10.08.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ:POZN),today announced results for the second quarter ended June 30, 2015. The Company highlighted important corporate, commercial, and regulatory updates from the quarter.

Total revenues resulting from VIMOVO® royalties for the three month period ended June 30, 2015, were $5.2 million, compared to total revenues of $7.4 million in the second quarter of 2014 that included $5.4 million of royalties and $2.0 million of amortization of the upfront fee for licensing of YOSPRALA, representing a decrease of thirty percent. Total revenues for the second quarter of 2015 increased 18% from the first quarter of 2015, reflecting royalty increases in both US and non-US markets. http://www.ariva.de/news/...ports-Second-Quarter-2015-Results-5452637  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  24.08.15      8,00      8,61§7,89 8,09 $ 867.007 7,11 M

GrB